Phio Pharmaceuticals Corp. announced on December 12, 2024, the publication of its manuscript, 'Self-delivering RNAi Immunotherapeutic PH-762 Silences PD-1 to Generate Local and Abscopal Anti-tumor Efficacy,' in the December 2024 issue of Frontiers in Immunology. The article presents preclinical proof-of-concept data for PH-762, an INTASYL compound designed to silence PD-1. PH-762 is currently undergoing clinical development for advanced cutaneous malignancies.
The publication highlights INTASYL's unique properties, including its selective gene targeting and potent silencing capabilities, positioning it as a promising candidate for solid tumor treatment. This peer-reviewed validation reinforces the scientific foundation of Phio's lead clinical program. The Editor-in-Chief of Frontiers in Immunology is Luigi Daniele Notarangelo, a prominent figure in clinical immunology.
The company also referenced recent data from the second cohort of its ongoing Phase 1b clinical trial, showing one patient with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance), and a second patient achieved a partial response (90% tumor clearance). This clinical progress, combined with the preclinical publication, strengthens the overall profile of PH-762.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.